Gabapentin Market PPT 2024: Size, Growth, Demand and Forecast till 2032
                     Global Gabapentin 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " G a b a p e n t i n  M a r k e t :  G l o b a l  I n d u s t r y  
T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  g l o b a l  g a b a p e n t i n  
m a r k e t  s i z e  r e a c h e d  U S $  2 . 2  B i l l i o n  i n  2 0 2 3 .
F a c t o r s  A f f e c t i n g  t h e  Gr o wt h  o f  th e  Ga b a p e n t i n  I n d u s t r y :
Report I n c re a se d  I n c i d en c e  o f  C h ro n i c  Pa i n  Co n d i t i o n s :T h e  r i s e  i n  t h e  i n c i d e n c e  o f  c h r o n i c  p a i n  c o n d i t i o n s  a m o n g  t h e  m a s s e s  i s  i m p e l l i n g  t h e  g r o w t h  
o f  t h e  m a r k e t .  G a b a p e n t i n ,  a n  a n t i c o n v u l s a n t  m e d i c a t i o n ,  i s  g a r n e r i n g  s i g n i f i c a n t  a t t e n t i o n  f o r  
Highlight and i t s  e f f i c a c y  i n  m a n a g i n g  n e u r o p a t h i c  p a i n .  A s  l i f e s t y l e s  b e c o m e  i n c r e a s i n g l y  s e d e n t a r y  a n d  c o n d i t i o n s  l i k e  d i a b e t e s  b e c o m e  m o r e  
p r e v a l e n t ,  i n d i v i d u a l s  a r e  a t  a  h i g h e r  r i s k  o f  d e v e l o p i n g  n e u r o p a t h i c  p a i n ,  o f t e n  a s s o c i a t e d  
Description w i t h  c o n d i t i o n s  l i k e  d i a b e t i c  n e u r o p a t h y  a n d  p o s t - h e r p e t i c  n e u r a l g i a .  T h i s  r i s e  i n  c h r o n i c  p a i n  c a s e s  i s  c a t a l y z i n g  t h e  d e m a n d  f o r  G a b a p e n t i n  a s  a  t r u s t e d  t r e a t m e n t  o p t i o n .
Ex p a n d i n g  A p p l ic a t i o n s  i n  N eu r o l o g i c a l  D i s o r d e rs :
T h e  a p p l i c a t i o n s  o f  G a b a p e n t i n  i n  n e u r o l o g i c a l  d i s o r d e r s  i s  p r o p e l l i n g  t h e  m a r k e t  g r o w t h .  
B e y o n d  i t s  w e l l - e s t a b l i s h e d  r o l e  i n  p a i n  r e l i e f ,  G a b a p e n t i n  h a s  p r o v e n  e f f e c t i v e  i n  m a n a g i n g  
e p i l e p s y  a n d  r e s t l e s s  l e g  s y n d r o m e .  A s  r e s e a r c h  c o n t i n u e s  t o  u n r a v e l  i t s  p o t e n t i a l  i n  d i v e r s e  
n e u r o l o g i c a l  c o n d i t i o n s ,  h e a l t h c a r e  p r o v i d e r s  a r e  i n c r e a s i n g l y  p r e s c r i b i n g  G a b a p e n t i n  t o  
a d d r e s s  t h e s e  d i s o r d e r s .
In  ep i lepsy management ,  Gabapent in  is  used as  an ad junct i ve  therapy 
a longs ide t rad i t iona l  an t iep i lep t i c  d rugs.  I t s  ab i l i t y  to  reduce  se izure  
f requency  and  improve  the qua l i ty  o f  l i fe  fo r  pat ien ts  w i th  ep i lepsy i s  
ca ta lyz ing  i t s  demand.
Growing Awareness and Acceptance:
The inc reas ing awareness  and  acceptance o f  the med icat ion among 
hea l thcare  pro fess iona ls  and  pa t ients  a l i ke  is  bo ls te r ing the  marke t  growth.  
Report Moreover ,  ex tens ive  c l in ica l  research has  h igh l ighted the  e f fec t i veness o f  
Gabapent in  in  manag ing  var ious cond i t ions ,  no t  on ly  l im i ted to  pa in  and 
Highlight and ep i lepsy,  bu t  a lso  ex tend ing  to  anx ie ty  d isorders  and b ipo la r  d isorder .  As 
th is  ev idence-based knowledge spreads ,  phys ic ians  a re  more inc l ined to  
Description cons ider  Gabapent in  as  a  t rea tment  op t ion,  lead ing to  h igher  p rescr ip t ion  ra tes .  
Moreover ,  pa t ients  themse lves  a re  becoming  more  in fo rmed about  the  
po ten t ia l  bene f i t s  o f  Gabapent in .  Onl ine  hea l th  resources and pa t ient  
communi t ies  a re  p lay ing  a  ro le  in  d issemina t ing  in fo rmat ion  and persona l  
exper iences wi th  medicat ion .  Th is  pa t ient -d r iven awareness is  lead ing  
ind iv idua ls  to  d iscuss Gabapent in  w i th  the i r  hea l thcare  p rov iders  and 
reques t  i t  as  par t  o f  the i r  t reatment  p lans.
Request  for  a  PDF sample  of  th is  report :  
ht tps : / /www. imarcgroup.com/gabapent in -marke t / requestsample
Report Description
Global Gabapentin Market Trends:
Pharmaceutical  companies are generat ing awareness about Gabapent in through research and 
development (R&D) and marketing in i t iat ives. They are invest ing in c l in ical  t r ia ls to explore new 
indicat ions for  Gabapent in and are developing extended-release formulat ions, providing 
pat ients wi th more convenient dosing opt ions. 
Furthermore, strategic market ing ef forts are increasing the vis ib i l i ty of  Gabapentin.  
Pharmaceutical  companies are also col laborat ing wi th heal thcare professionals to promote the 
benef i ts of  the medicat ion and educate them about i ts  var ious appl icat ions. This col laborat ion is  
resul t ing in a higher level  of  comfort among physic ians when prescr ib ing Gabapent in.
View Report TOC, Figures and Tables :  https://www.imarcgroup.com/gabapentin-market
Breakup by Dosage Form:
• Tablet
• Capsule
• Oral  Solutions
Breakup by Type:
Report • Generic
• Branded
Segmentation
Breakup by Application:
• Epi lepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Others
Breakup by Distribution Channel:
• Hospital  Pharmacy
• Retai l  Pharmacy
• Online Pharmacy
Report Breakup by Region:
• North America
Segmentation
• Europe
• Asia-Pacifi c
• Latin America
• Middle East and Afr ica
• Alkem Laboratories Limited
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Aurobindo Pharma Limited
Competitive • Azurity Pharmaceuticals,  Inc.
• Cipla Inc.
Landscape 
• Glenmark Pharmaceuticals Limited
with Key • Pfi zer Inc.
Players • Sun Pharmaceutical  Industries Ltd.
• Teva Pharmaceutical  Industr ies Ltd.
• Viatr is  Inc.
• Zydus Pharmaceuticals (USA) Inc. (Zydus 
Li feScience).
How has the global gabapentin market performed so 
far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in 
the global market?
What is the impact of each driver, restraint, and 
Key opportunity on the global market?
Questions What are the key regional markets?
Answered in 
Which countries represent the most attractive market?
the Report
What is the breakup of the market based on the dosage 
form?
Which is the most attractive dosage form in the market?
What is the breakup of the market based on the type?
Which is the most attractive type in the market?
What is the breakup of the market based on the 
application?
Key Which is the most attractive application in the market?
Questions What is the breakup of the market based on the 
distribution channel?
Answered in 
the Report Which is the most attractive distribution channel in the market?
What is the competitive structure of the market?
Who are the key players/companies in the global 
gabapentin market?
1     P r e f a c e
2  S c o p e  a n d  M e t h o d o l o g y
2 . 1  O b j e c t i v e s  o f  t h e  S t u d y
2 . 2  S t a k e h o l d e r s
2 . 3  D a t a  S o u r c e s
2 . 3 . 1  P r i m a r y  S o u r c e s
2 . 3 . 2  S e c o n d a r y  S o u r c e s
2 . 4  M a r k e t  E s t i m a t i o n
2 . 4 . 1  B o t t o m - U p  A p p r o a c h
Table of 2 . 4 . 2  T o p - D o w n  A p p r o a c h2 . 5  F o r e c a s t i n g  M e t h o d o l o g y
3  E x e c u t i v e  S u m m a r y
4  G l o b a l  G a b a p e n t i n  M a r k e t  -  I n t r o d u c t i o n
4 . 1  O v e r v i e w
Contents 4 . 2  M a r k e t  D y n a m i c s4 . 3  I n d u s t r y  T r e n d s
4 . 4  C o m p e t i t i v e  I n t e l l i g e n c e
5  G l o b a l  G a b a p e n t i n  M a r k e t  L a n d s c a p e
5 . 1  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
5 . 2  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6  G l o b a l  G a b a p e n t i n  M a r k e t  -  B r e a k u p  b y  D o s a g e  F o r m
6 . 1  T a b l e t
6 . 1 . 1  O v e r v i e w
6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 1 . 3  M a r k e t  S e g m e n t a t i o n
6 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6 . 2  C a p s u l e  
6 . 2 . 1  O v e r v i e w
6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 2 . 3  M a r k e t  S e g m e n t a t i o n
6 . 2 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
6 . 3  O r a l  S o l u t i o n s
6 . 3 . 1  O v e r v i e w
6 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
6 . 3 . 3  M a r k e t  S e g m e n t a t i o n
6 . 3 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6 . 4  A t t r a c t i v e  I n v e s t m e n t  P r o p o s i t i o n  b y  D o s a g e  F o r m
7  G l o b a l  G a b a p e n t i n  M a r k e t  -  B r e a k u p  b y  T y p e
7 . 1  G e n e r i c
7 . 1 . 1  O v e r v i e w
7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
7 . 1 . 3  M a r k e t  S e g m e n t a t i o n
Table of 7 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )7 . 2  B r a n d e d  
7 . 2 . 1  O v e r v i e w
Contents 7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )7 . 2 . 3  M a r k e t  S e g m e n t a t i o n
7 . 2 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
7 . 3  A t t r a c t i v e  I n v e s t m e n t  P r o p o s i t i o n  b y  T y p e
8  G l o b a l  G a b a p e n t i n  M a r k e t  -  B r e a k u p  b y  A p p l i c a t i o n
8 . 1  E p i l e p s y
8 . 1 . 1  O v e r v i e w
8 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
8 . 1 . 3  M a r k e t  S e g m e n t a t i o n
8 . 1 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
8 . 2  N e u r o p a t h i c  P a i n
8 . 2 . 1  O v e r v i e w
8 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
8 . 2 . 3  M a r k e t  S e g m e n t a t i o n
8 . 2 . 4  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /g a ba pen t i n -ma rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: